<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">The World Health Organization</segment>
<segment id="3" parent="2" relname="restatement">( WHO )</segment>
<segment id="4" parent="1003" relname="same_unit">classifies gliomas into four categories</segment>
<segment id="5" parent="1005" relname="span">based on malignancy and overall survival</segment>
<segment id="6" parent="5" relname="elaboration">( OS ) .</segment>
<segment id="7" parent="1008" relname="span">Glioblastoma is the most malignant form of astrocytoma</segment>
<segment id="8" parent="7" relname="elaboration">that is fast-growing</segment>
<segment id="9" parent="1008" relname="elaboration">( grade 4 glioma ) .</segment>
<segment id="10" parent="1010" relname="joint">The median OS of glioblastoma is 9 – 15 months</segment>
<segment id="11" parent="1010" relname="joint">and the five-year survival rate remains less than 5 % .</segment>
<segment id="12" parent="1011" relname="joint">Radiotherapy with six cycles of concomitant temozolomide , an oral alkylating agent with minimal additional toxicity ,</segment>
<segment id="13" parent="1012" relname="joint">is the standard treatment after surgery in glioblastoma patients .</segment>
<segment id="14" parent="1014" relname="span">Thus , there is an immediate requirement for the early diagnosis and precise prediction of the prognosis for treatments of glioblastoma .</segment>
<segment id="15" parent="1015" relname="span">The invasiveness of glioblastoma depends on its high infiltration potential</segment>
<segment id="16" parent="15" relname="purpose">to invade the basement membranes of surrounding tissues .</segment>
<segment id="17" parent="1018" relname="span">Glioma cells are reprogrammed</segment>
<segment id="18" parent="17" relname="purpose">to have increased motility via weakened cell adhesions and a dysregulated cytoskeleton ;</segment>
<segment id="19" parent="1019" relname="span">this is known as epithelial – mesenchymal transition</segment>
<segment id="20" parent="19" relname="elaboration">( EMT ) .</segment>
<segment id="21" parent="1022" relname="span">EMT is a biological process</segment>
<segment id="22" parent="21" relname="elaboration">that polarized epithelial cell sheets undergo ,</segment>
<segment id="23" parent="1021" relname="same_unit">wherein multiple biochemical changes culminate in mesenchymal phenotypes .</segment>
<segment id="24" parent="1024" relname="span">Cells display altered morphology , resistance to chemotherapy , and anoikis</segment>
<segment id="25" parent="24" relname="elaboration">( a form of programmed cell death of cells detached from the basement membranes ) .</segment>
<segment id="26" parent="1026" relname="span">EMT is also involved in other biological processes ,</segment>
<segment id="27" parent="1027" relname="span">including implantation and embryo development , wound healing , tissue regeneration , and neoplasia</segment>
<segment id="28" parent="27" relname="elaboration">associated with cancer progression .</segment>
<segment id="29" parent="1030" relname="attribution">During invasion in cancer , phenotypes also change</segment>
<segment id="30" parent="1031" relname="span">as EMT is mainly induced by hypoxia and the transforming growth factor</segment>
<segment id="31" parent="1032" relname="span">( TGF)-β</segment>
<segment id="32" parent="1033" relname="span">released from glioma stem cells</segment>
<segment id="33" parent="32" relname="elaboration">( GSCs ) ,</segment>
<segment id="34" parent="1035" relname="span">mesenchymal stem cells</segment>
<segment id="35" parent="34" relname="elaboration">( MSCs ) , and myeloid cells</segment>
<segment id="36" parent="1035" relname="elaboration">recruited by hypoxia .</segment>
<segment id="37" parent="1036" relname="joint">The reverse is also essential for the formation of distant or disseminated tumor nodules .</segment>
<segment id="38" parent="1040" relname="span">Stem cells , including cancer stem cells</segment>
<segment id="39" parent="38" relname="elaboration">( CSCs ) ,</segment>
<segment id="40" parent="1041" relname="span">are pluripotent and capable of self-renewal , like induced pluripotent stem</segment>
<segment id="41" parent="40" relname="restatement">( iPS )</segment>
<segment id="42" parent="1042" relname="span">cells</segment>
<segment id="43" parent="42" relname="elaboration">induced by the transcription factors Oct3/4 , Sox2 , c-Myc , and Klf4 or OCT4 , SOX2 , NANOG , and LIN28 .</segment>
<segment id="44" parent="1044" relname="span">The expression of OCT4 , MYC , and KLF4 increases with increasing malignancy in astrocytomas ,</segment>
<segment id="45" parent="44" relname="circumstance">whereas MYC expression slightly decreases in recurrent glioblastomas .</segment>
<segment id="46" parent="1047" relname="span">Exposure to temozolomide</segment>
<segment id="47" parent="46" relname="restatement">( TMZ )</segment>
<segment id="48" parent="1048" relname="joint">increases the expression of KLF4</segment>
<segment id="49" parent="1049" relname="span">and reduces the expression of Nanog and OCT4 in glioma cells ,</segment>
<segment id="50" parent="49" relname="elaboration">indicating that stem cell factors , especially KLF4 , play pivotal roles in GSCs .</segment>
<segment id="51" parent="1051" relname="joint">The most common GSC marker CD133 ,</segment>
<segment id="52" parent="1055" relname="span">also known as prominin-1</segment>
<segment id="53" parent="52" relname="elaboration">( PROM1 ) ,</segment>
<segment id="54" parent="1054" relname="same_unit">is used</segment>
<segment id="55" parent="1056" relname="span">to isolate GSCs by fluorescence-activated cell sorting</segment>
<segment id="56" parent="55" relname="elaboration">( FACS )</segment>
<segment id="57" parent="1052" relname="same_unit">in primary glioma tissues and the cell lines U87 and T98G .</segment>
<segment id="58" parent="1058" relname="joint">There are changes in metabolism in glioma</segment>
<segment id="59" parent="1058" relname="joint">and oxidative phosphorylation , glycolysis , and glutaminolysis replace redox balance , bioenergetics , and biosynthesis , respectively .</segment>
<segment id="60" parent="1060" relname="span">Tumor progression is enhanced by inflammation ,</segment>
<segment id="61" parent="1061" relname="span">which is an emerging hallmark of cancers</segment>
<segment id="62" parent="61" relname="elaboration">that depends on the balance of glioma cell proliferation , migration , and escape from the immune system .</segment>
<segment id="63" parent="1063" relname="preparation">However , the correlation between EMT and GSCs in glioblastoma has not been reported to date .</segment>
<segment id="64" parent="1065" relname="sequence">In this study , we focused on EMT and GSCs</segment>
<segment id="65" parent="1066" relname="span">and performed multivariable analyses</segment>
<segment id="66" parent="65" relname="means">using the expression data and OS in patients with glioblastoma .</segment>
<segment id="67" parent="1067" relname="span">To determine the distribution of survival of glioblastoma patients , we composed prognosis prediction formulae for the following components :</segment>
<segment id="68" parent="1069" relname="span">epithelium</segment>
<segment id="69" parent="1070" relname="span">( EPI ) , mesenchyme</segment>
<segment id="70" parent="69" relname="elaboration">( MES ) ,</segment>
<segment id="71" parent="1072" relname="span">glioma</segment>
<segment id="72" parent="71" relname="elaboration">( GLI ) ,</segment>
<segment id="73" parent="1074" relname="span">GSC , molecular target therapy</segment>
<segment id="74" parent="73" relname="restatement">( MTT )</segment>
<segment id="75" parent="1075" relname="span">genes , and potential glioma biomarkers</segment>
<segment id="76" parent="75" relname="elaboration">( PGBs ) .</segment>
<segment id="77" parent="1063" relname="joint">Consequently , several candidate genes were identified as promising glioblastoma predictors .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1006" relname="background"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="span" parent="1003" relname="elaboration"/>
<group id="1006" type="span" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="multinuc" parent="1007" relname="elaboration"/>
<group id="1010" type="multinuc" parent="1009" relname="joint"/>
<group id="1011" type="multinuc" parent="1009" relname="joint"/>
<group id="1012" type="multinuc" parent="1011" relname="joint"/>
<group id="1013" type="multinuc" parent="1012" relname="joint"/>
<group id="1014" type="span" parent="1013" relname="joint"/>
<group id="1015" type="span" parent="14" relname="elaboration"/>
<group id="1016" type="multinuc" parent="1013" relname="joint"/>
<group id="1017" type="multinuc" parent="1016" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="same_unit"/>
<group id="1019" type="span" parent="1017" relname="same_unit"/>
<group id="1020" type="multinuc" parent="1016" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="same_unit"/>
<group id="1023" type="multinuc" parent="1020" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="joint"/>
<group id="1025" type="multinuc" parent="1023" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1028" type="multinuc" parent="1025" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="span" parent="30" relname="elaboration"/>
<group id="1033" type="span" parent="31" relname="elaboration"/>
<group id="1034" type="span" parent="1030" relname="same_unit"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="multinuc" parent="1028" relname="joint"/>
<group id="1037" type="multinuc" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="1037" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="same_unit"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1041" type="span" parent="1039" relname="same_unit"/>
<group id="1042" type="span" parent="1038" relname="same_unit"/>
<group id="1043" type="multinuc" parent="1037" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1043" relname="joint"/>
<group id="1046" type="multinuc" parent="1045" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="same_unit"/>
<group id="1048" type="multinuc" parent="1046" relname="same_unit"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="multinuc" parent="1045" relname="joint"/>
<group id="1051" type="multinuc" parent="1050" relname="joint"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="same_unit"/>
<group id="1054" type="multinuc" parent="1053" relname="span"/>
<group id="1055" type="span" parent="1054" relname="same_unit"/>
<group id="1056" type="span" parent="1054" relname="purpose"/>
<group id="1057" type="multinuc" parent="1050" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="span" parent="1057" relname="joint"/>
<group id="1060" type="span" parent="1062" relname="concession"/>
<group id="1061" type="span" parent="60" relname="elaboration"/>
<group id="1062" type="span" parent="1059" relname="span"/>
<group id="1063" type="multinuc" parent="1062" relname="span"/>
<group id="1064" type="span" parent="1063" relname="joint"/>
<group id="1065" type="multinuc" parent="1064" relname="span"/>
<group id="1066" type="span" parent="1065" relname="sequence"/>
<group id="1067" type="span" parent="1065" relname="purpose"/>
<group id="1068" type="multinuc" parent="67" relname="elaboration"/>
<group id="1069" type="span" parent="1068" relname="same_unit"/>
<group id="1070" type="span" parent="68" relname="elaboration"/>
<group id="1071" type="multinuc" parent="1068" relname="same_unit"/>
<group id="1072" type="span" parent="1071" relname="same_unit"/>
<group id="1073" type="multinuc" parent="1071" relname="same_unit"/>
<group id="1074" type="span" parent="1073" relname="same_unit"/>
<group id="1075" type="span" parent="1073" relname="same_unit"/>
	</body>
</rst>
